We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vacci... Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States. Show more
Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ...
Delta Air Lines (NYSE:DAL) – Delta Airlines reported a first-quarter profit of $37 million, a significant increase compared to the $363 million loss from the previous year. With adjusted...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C...
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the first patient has been dosed in the REJOICE-Ovarian01 phase 2/3...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its first-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m...
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results and represents the sixth approval for KEYTRUDA in lung...
GameStop (NYSE:GME) – GameStop reported $1.79 billion in revenue for the fourth quarter, which is less than the $2.23 billion earned in the same quarter of the previous year. However, the...
WINREVAIR is a breakthrough biologic for this rare, progressive disease WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 1.09 | 0.863503129209 | 126.23 | 128.1 | 124.5 | 7408892 | 126.09767572 | CS |
4 | -5.55 | -4.17701512757 | 132.87 | 133.1 | 124.5 | 7188501 | 127.97158844 | CS |
12 | 4.79 | 3.90924671509 | 122.53 | 133.1 | 119.41 | 8354433 | 125.48504215 | CS |
26 | 24.12 | 23.3720930233 | 103.2 | 133.1 | 99.8 | 8352888 | 116.18949581 | CS |
52 | 11.47 | 9.90073370738 | 115.85 | 133.1 | 99.14 | 7691379 | 113.00912309 | CS |
156 | 49.32 | 63.2307692308 | 78 | 133.1 | 70.89 | 9978757 | 93.32870577 | CS |
260 | 52.59 | 70.3733440385 | 74.73 | 133.1 | 65.25 | 9979193 | 88.24148854 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions